OA
ONC icon

Operose Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Operose Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10
Closed -$1.85K – 458
2024
Q4 		$1.85K Buy
+10
New +$2.04K ﹤0.01% 400

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Operose Advisors's ONC Position: Q1 2025 in Review

Operose Advisors sold out of BeOne Medicines Ltd (ONC) in Q1 2025, closing a stake of 10 shares — an estimated $1.85K sold.

Operose Advisors first reported a position in ONC in Q4 2024 and held it in 1 quarter. The position peaked at $1.85K in Q4 2024. 268 funds tracked by Wall St. Rank hold ONC as of Q1 2025.

  • Operose Advisors reported no remaining BeOne Medicines Ltd position as of Q1 2025 after selling out during the quarter.
  • Operose Advisors sold 10 BeOne Medicines Ltd shares in Q1 2025, an estimated $1.85K.
  • Operose Advisors first reported a position in BeOne Medicines Ltd in Q4 2024 and held it in 1 quarter.
  • Operose Advisors's BeOne Medicines Ltd position peaked at $1.85K in Q4 2024.
  • 268 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2025.

Based on Operose Advisors's 13F filing for Q1 2025, filed 12 May 2025.